Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 29,7 M
EBIT 2016 -8,85 M
Net income 2016 -8,75 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 -
Capi. / Sales2016 1,82x
Capi. / Sales2017 -
Capitalization 54,1 M
More Financials
Company
Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir... 
More about the company
Latest news on BIOTA PHARMACEUTICALS INC
07/15 AVIRAGEN THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-..
07/14 AVIRAGEN THERAPEUTICS : licenses Georgia State Technology to develop antiviral t..
07/13 AVIRAGEN THERAPEUTICS, INC. : Other Events (form 8-K)
07/12 Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
07/07 HealthCare Royalty Partners Commits $205 Million to New Investments Over the ..
07/05 Aviragen Therapeutics and Georgia State University Research Foundation Enter ..
07/02 AVIRAGEN THERAPEUTICS : Announces Inducement Grant for New Employee
07/01 Aviragen Therapeutics Announces Inducement Grant for New Employee
06/29 AVIRAGEN THERAPEUTICS : Announces the Appointment of Jonas Niaura as Vice Presid..
06/28 Aviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice Presi..
More news
Sector news : Bio Therapeutic Drugs
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 2
Average target price 5,50 $
Spread / Average Target 293%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph M. Patti President, Chief Executive Officer & Director
Russell H. Plumb Executive Chairman
Mark P. Colonnese Chief Financial Officer & Executive Vice President
Anna Novotney-Barry Vice President-Clinical Development
John H. Vernachio Vice President-Preclinical Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS ..54
AMGEN, INC.5.24%127 850
GILEAD SCIENCES, INC.-20.45%106 233
CELGENE CORPORATION-7.65%85 728
REGENERON PHARMACEUTIC..-25.35%42 671
VERTEX PHARMACEUTICALS..-23.14%23 963
More Results